In Q2 2025, Deep Track Capital held 57 positions worth $2.9B. They initiated 2 new positions and exited 63. Their largest holding was GH ($221.2M). Portfolio value shrank -0.0% versus the prior quarter.
Frequently asked questions
What stocks did Deep Track Capital own in Q2 2025?
Deep Track Capital held 57 biotech stocks in their 13F portfolio in Q2 2025. Their top positions include GH, IONS, PTGX, DVAX, INSM. The full holdings table is available on BiotechEdge with position sizes, quarter-over-quarter changes, and AI analysis.
How much was Deep Track Capital's portfolio worth in Q2 2025?
Deep Track Capital's tracked biotech portfolio was worth $2.9B across 57 positions, with total assets under management of approximately $5B. Portfolio values are based on 13F filings with the SEC.
What did Deep Track Capital buy in Q2 2025?
Deep Track Capital initiated 2 new positions in Q2 2025, including JBIO, CBIO. They also increased 20 existing positions.
What did Deep Track Capital sell in Q2 2025?
Deep Track Capital fully exited 63 positions in Q2 2025, including FATE, NTLA, KURA, KYMR, PRTA and 58 more. They also trimmed 19 existing positions.
Is Deep Track Capital a biotech fund?
Greenwich-based life sciences investment advisor founded by David Kroin, who previously co-founded Great Point Partners. Invests across public and private biotech, pharmaceutical, and medical device companies with over 25 years of healthcare investment expertise driving concentrated, high-conviction positioning.
Want AI analysis, insider signals, and catalyst overlays for Deep Track Capital?
View latest Deep Track Capitalportfolio →